Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.

Lu X, Williams Z, Hards K, Tang J, Cheung CY, Aung HL, Wang B, Liu Z, Hu X, Lenaerts A, Woolhiser L, Hastings C, Zhang X, Wang Z, Rhee K, Ding K, Zhang T, Cook GM.

ACS Infect Dis. 2019 Feb 8;5(2):239-249. doi: 10.1021/acsinfecdis.8b00225. Epub 2018 Dec 11.

PMID:
30485737
2.

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.

Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.

3.

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.

Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snavely T, Robertson GT, Rubin EJ, Ioerger TR, Sirgel FA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts AJ, Sacchettini JC.

Cell. 2017 Jul 13;170(2):249-259.e25. doi: 10.1016/j.cell.2017.06.025. Epub 2017 Jun 29.

4.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

5.

Mycobacterium tuberculosis Lsr2 is a global transcriptional regulator required for adaptation to changing oxygen levels and virulence.

Bartek IL, Woolhiser LK, Baughn AD, Basaraba RJ, Jacobs WR Jr, Lenaerts AJ, Voskuil MI.

MBio. 2014 Jun 3;5(3):e01106-14. doi: 10.1128/mBio.01106-14.

6.

Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.

Rakesh, Bruhn DF, Scherman MS, Woolhiser LK, Madhura DB, Maddox MM, Singh AP, Lee RB, Hurdle JG, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE.

PLoS One. 2014 Feb 5;9(2):e87909. doi: 10.1371/journal.pone.0087909. eCollection 2014.

7.

Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.

Ekins S, Reynolds RC, Kim H, Koo MS, Ekonomidis M, Talaue M, Paget SD, Woolhiser LK, Lenaerts AJ, Bunin BA, Connell N, Freundlich JS.

Chem Biol. 2013 Mar 21;20(3):370-8. doi: 10.1016/j.chembiol.2013.01.011.

8.

Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer.

Fávaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Durán N, Lenaerts AJ.

Infect Agent Cancer. 2012 Jun 18;7(1):14. doi: 10.1186/1750-9378-7-14.

9.

Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.

Gonzalez-Juarrero M, Woolhiser LK, Brooks E, DeGroote MA, Lenaerts AJ.

Antimicrob Agents Chemother. 2012 Jul;56(7):3957-9. doi: 10.1128/AAC.00464-12. Epub 2012 Apr 30.

10.

Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

De Groote MA, Gruppo V, Woolhiser LK, Orme IM, Gilliland JC, Lenaerts AJ.

Antimicrob Agents Chemother. 2012 Feb;56(2):731-8. doi: 10.1128/AAC.05701-11. Epub 2011 Dec 5.

11.

A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.

Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, Boom WH, Belisle JT.

Antimicrob Agents Chemother. 2012 Jan;56(1):28-35. doi: 10.1128/AAC.05486-11. Epub 2011 Oct 28.

12.

Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.

Mathew B, Srivastava S, Ross LJ, Suling WJ, White EL, Woolhiser LK, Lenaerts AJ, Reynolds RC.

Bioorg Med Chem. 2011 Dec 1;19(23):7120-8. doi: 10.1016/j.bmc.2011.09.062. Epub 2011 Oct 5.

13.

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V, Peloquin CA, Orme IM, Lenaerts AJ.

Antimicrob Agents Chemother. 2011 Mar;55(3):1237-47. doi: 10.1128/AAC.00595-10. Epub 2010 Dec 6.

14.

Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity.

Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE.

Bioorg Med Chem. 2009 May 15;17(10):3588-94. doi: 10.1016/j.bmc.2009.04.005. Epub 2009 Apr 9.

15.

Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice.

Woolhiser LK, Hoff DR, Marietta KS, Orme IM, Lenaerts AJ.

Antimicrob Agents Chemother. 2009 Jan;53(1):306-8. doi: 10.1128/AAC.01346-07. Epub 2008 Oct 13.

16.

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS, Johnson CM, Orme IM.

Antimicrob Agents Chemother. 2008 Apr;52(4):1513-5. doi: 10.1128/AAC.00897-07. Epub 2008 Feb 11.

17.

In vivo adaptation of the Wayne model of latent tuberculosis.

Woolhiser L, Tamayo MH, Wang B, Gruppo V, Belisle JT, Lenaerts AJ, Basaraba RJ, Orme IM.

Infect Immun. 2007 May;75(5):2621-5. Epub 2007 Feb 5.

Supplemental Content

Loading ...
Support Center